Syneos Health announced the release of its survey “Real World Value: Advancing Payer Understanding of RWE in Rare Disease.” The survey talks about the perception gap that payers have surrounding RWE benefits for rare disease therapies. It also provides feedback from more than 300 payers in the U.S. and Europe, exploring the acceptability of RWE on payer decisions for rare therapies and perspectives on how their stance is likely to evolve over time.
Some of the survey findings include:
Read or download the full report here.
The Weight-Loss Gold Rush: Legal and Regulatory Implications
July 11th 2024Jim Shehan, chair of the FDA Regulatory practice, Lowenstein Sandler, discusses how the FDA and other regulators likely to respond to the increased public interest and potential off-label use of GLP-1 drugs, what needs to be done for GLP-1s to be covered, advice for investors and financiers considering entering the weight-loss medication market and more.
Healthcare Marketing Strategies for Reaching Diverse Audiences
May 14th 2024Amanda Powers-Han, Chief Marketing Officer, Greater Than One, and Pharmaceutical Executive Editorial Advisory Board member, discusses how improved DE&I in healthcare marketing strategies can not only reach diverse audiences more effectively but also contribute to improved patient care outcomes, challenges faced in crafting culturally sensitive messages, and much more.